 RALEIGH, NC ACCESSWIRE February 9, 2022 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President Chief Executive Officer of 9 Meters Biopharma, Inc., will deliver a virtual presentation as part of the 2022 BIO CEO Investor Conference taking place February 14-17, 2022. Registered attendees of the conference will have access to an on-demand presentation highlighting the Companys advanced pipeline and upcoming clinical milestones for vurolenatide, its long-acting GLP-1 agonist for short bowel syndrome currently in a Phase 2 clinical study, and larazotide, its Phase 3 tight junction regulator for celiac disease. 